Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.87Last Year’s EPS
-0.82Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum (notably KT-621 and KT-579), significant balance sheet strength (raised ~ $1B; $1.6B year-end cash) and multiple high-value collaborations, all supporting an ambitious development plan. Headwinds include elevated R&D spend (adjusted cash R&D +16% QoQ), limited current revenue, translational/measurement complexity for IRF5, and multi-year timelines to pivotal readouts and potential approvals. Overall, the positives—compelling early clinical data, IND/Phase I starts, partner validation and a multi-year cash runway—outweigh the noted operational and timing risks.Company Guidance
KT-621 (STAT6 Degrader) Strong Early Clinical Data
Phase I healthy volunteer and Phase Ib BroADen data showed robust STAT6 degradation, favorable safety/tolerability and meaningful reductions in Type 2 biomarkers (TARC, Eotaxin-3) and lung FeNO; clinical endpoints (EASI, Pruritus NRS, IGA, SCORAD, PROs) were in line with or numerically exceeded published dupilumab data at 4 weeks.
KT-621 Late-Stage Progression and Trial Design
Two parallel Phase IIb dose-ranging, placebo-controlled trials launched: BROADEN2 (AD, ~200 adults/adolescents, primary endpoint % change in EASI at 16 weeks; enrollment expected complete by end-2026; topline mid-2027) and BREADTH (asthma, ~264 adults with eosinophilic asthma, primary endpoint change in pre-bronchodilator FEV1 at 12 weeks; data expected late-2027). Combined expectation: ~500 patients generating data next year.
KT-621 Toxicology and Long-Term Safety Plans
Completed 6–9 month GLP toxicology studies in rats and nonhuman primates for KT-621 with no adverse findings reported; long-term treatment data being collected via a 52-week open-label extension for AD patients.
KT-579 (IRF5 Degrader) IND Clearance and Phase I Start
KT-579 IND cleared and dosing initiated in a Phase I single/multiple ascending dose healthy volunteer study; primary translational objective is ~90% IRF5 reduction in blood and ex vivo assays expect 50%–80% reductions in TLR7/8/9-driven biomarkers; first-in-human data anticipated in H2 2026 and patient POC (lupus) planned thereafter.
Collaborations and Partner Validation
Gilead collaboration included a $40M upfront payment and up to $750M in milestones (including a $45M option payment); Sanofi partnership for KT-485 (IRAK4 degrader) can realize ~"nearly $1 billion" in milestones; Q4 2025 collaboration revenue was $2.9M attributable to Gilead.
Strong Balance Sheet and Runway
Raised almost $1.0 billion in 2025; year-end cash balance $1.6 billion, which management states provides runway into 2029 and funds completion of both KT-621 Phase IIb trials and a large part of first Phase III.
Leadership and Pipeline Expansion
Hired Neil Graham as Chief Development Officer (30+ years in drug development, including dupilumab leadership); continued internal pipeline advancement with plan to announce at least one new program annually and target a new development candidate in H2 2026.
Operational and Strategic Positioning
Clear regulatory and development strategy: use AD Phase IIb to support other dermatologic indications and asthma Phase IIb to support other respiratory indications; intent to move to registrational/Phase III studies after Phase II completion and FDA discussion.
KYMR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KYMR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $90.68 | $95.03 | +4.80% |
Nov 04, 2025 | $59.72 | $59.91 | +0.32% |
Aug 11, 2025 | $40.62 | $37.68 | -7.24% |
May 09, 2025 | $30.77 | $30.07 | -2.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Kymera Therapeutics (KYMR) earnings time?
Kymera Therapeutics (KYMR) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYMR EPS forecast?
KYMR EPS forecast for the fiscal quarter 2026 (Q1) is -0.87.